Rare disease treatment sponsors and advocates may prefer all US Food and Drug Administration teams give the same development advice, but that may not be possible across all classes of products, regulators caution.
Inconsistent advice not only occurs within the FDA’s drug and biologic offices, but between the centers. Center for Biologics Evaluation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?